Is Xencor, Inc. (XNCR) a Buy, Sell, or Hold?
NASDAQ : XNCR
Xencor, Inc.
$14.98 USD
$0.03 (0.2%)
- Volume
- 451.28K
- Average Volume
- 829.26K
- Market Capitalization
- $1.11B
- P/E Ratio
- -6.54
- Dividend Yield
- 0.00%
- Price Target
- $27.00
- Year High
- $18.69
- Year Low
- $6.92
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.57
| Source | Headline |
|---|---|
|
Xencor: Bullish On Their Increasingly In-House Pipeline
Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR's oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR's valuation in the near term. seekingalpha.com - 2026-07-14 16:01:56 |
|
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a gurufocus.com - 2026-05-18 09:00:00 |
|
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript seekingalpha.com - 2026-05-13 03:40:47 |
|
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago. zacks.com - 2026-05-06 18:11:06 |
|
Xencor Reports First Quarter 2026 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. “Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for t. businesswire.com - 2026-05-06 16:01:00 |
|
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript seekingalpha.com - 2026-05-05 18:41:19 |
|
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease (IBD). The results are being presented today at Digestive Disease Week® (DDW), being held in Chicago. Tomorrow, the company will a. businesswire.com - 2026-05-04 08:01:00 |
